INSM Stock Summary and Trading Ideas (Insmed | NASDAQ:INSM)

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Insmed trades on the NASDAQ stock market under the symbol INSM.

As of August 26, 2026, INSM stock price climbed to $124.39 with 1,265,061 million shares trading.

INSM has a beta of 0.76, meaning it tends to be less sensitive to market movements. INSM has a correlation of 0.02 to the broad based SPY ETF.

INSM has a market cap of $27.16 billion. This is considered a Large Cap stock.

Last quarter Insmed reported $425 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $36 million and exceeded earnings estimates by $.68.

In the last 3 years, INSM traded as high as $212.75 and as low as $21.21.

The top ETF exchange traded funds that INSM belongs to (by Net Assets): VTI, VXF, VB, VO, IBB.

INSM has underperformed the market in the last year with a price return of -3.1% while the SPY ETF gained +20.4%. However, in the short term, INSM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +17.1% vs +3.0% return in SPY. But in the last 2 weeks, INSM shares have been beat by the market, returning -6.2% compared to an SPY return of -0.6%.

INSM support price is $121.04 and resistance is $126.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INSM shares will trade within this expected range on the day.